2012 Drug Repositioning Conference Highlights

The second annual Drug Repositioning and Indications Discovery Conference was held again in the San Francisco Bay Area on Oct 23-24.

http://dx.doi.org/10.1016/j.drudis.2012.08.005

from: http://dx.doi.org/10.1016/j.drudis.2012.08.005

 

Similar to last year, Dr. Barry Bunin chaired an exciting panel discussion. Perhaps co-hosting this Drug Repositioning Summit will become an annual tradition for CDD!

This year’s distinguished panelists included Dr. Christine Colvis, who heads the promising new NIH NCATS Therapeutics Discovery Program for drug repositioning, Dr. Christopher Lipinski (CDD SAB member), and Dr. David Cavalla, the founder of Numedicus Ltd, called in from the UK.

Dr. Cristine Colvis talked about the NCATS program at the NIH with it’s focus on the actual science of the translational process, NIH-Pharma-Academic Collaborations, and the power of crowd-sourcing in drug repositioning efforts. Dr. Christopher Lipinski emphasized that the repositioning methods need not be the same as target-based discovery methods, given the limitations of mechanistic and reductionist approaches of drug discovery versus the complexity of real biological systems. This point about the immensity of biological complexity was re-emphasized by Dr. David Cavalla, who went on to discuss the ontological and other in-silico predictive approaches to repurposing.

Listen to the full panel discussion here. Download the full slide decks and watch each speaker’s presentations on CDD’s resources page.